Acadia updates 2025 guidance, targets over $1B in revenue as DAYBUE and NUPLAZID reach milestone growth
Earnings Call Insights: ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Catherine Owen Adams, CEO, reported "another strong...
Tag: ACAD
Acadia Pharma GAAP EPS of $0.42 beats by $0.28, revenue of $278.6M beats by $2.06M
Acadia Pharma press release (ACAD): Q3 GAAP EPS of $0.42 beats by $0.28. Revenue of $278.6M (+11.3% Y/Y) beats by $2.06M....
Acadia Pharma Q3 2025 Earnings Preview
Acadia Pharma (ACAD) is scheduled to announce Q3 earnings results on Wednesday, November 5th, after market close. The...
Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps
Acadia Pharma (NASDAQ:ACAD) shares fell in the premarket on Wednesday after the biotech announced that its experimental...
Acadia raises 2025 NUPLAZID guidance to $665M–$690M as DAYBUE accelerates community uptake
Earnings Call Insights: ACADIA Pharmaceuticals (ACAD) Q2 2025 Catherine E. Owen Adams, CEO, stated that "Our second quarter...
Acadia Pharma Q2 2025 Earnings Preview
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q2 earnings results on Wednesday, August 6th, after market close. The...
Acadia Pharma GAAP EPS of $0.16 beats by $0.03, revenue of $264.6M beats by $2.6M
Acadia Pharma press release (NASDAQ:ACAD): Q2 GAAP EPS of $0.16 beats by $0.03. Revenue of $264.6M (+9.4% Y/Y) beats by...
Acadia gets court approval related to Nuplazid patent
AndreyPopov/iStock via Getty Images Acadia Pharmaceuticals (NASDAQ:ACAD) said on Monday that the U.S. Court of Appeals...
Acadia Pharmaceuticals jumps after win in patent suit over Nuplazid
wildpixel/iStock via Getty ImagesAcadia Pharmaceuticals (NASDAQ:ACAD) soared 20% after a court ruling in patent suit...
Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders
Acadia Pharmaceuticals (NASDAQ:ACAD) files a prospectus for the offer and sale of 43.6M shares of common stock by the...